1 Min Read
Nov 29 (Reuters) - Proqr Therapeutics Nv:
* PROQR RECEIVES ORPHAN DRUG DESIGNATION FROM EMA FOR DRUG CANDIDATE QR-313 FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.